Insights On Enterprise Solutions
-
Mechanochemistry- Enabled Solid-State Stress Testing
5/6/2026
Discover how solvent‑free, solid‑state stress testing speeds degradation studies, yields realistic impurity profiles, and provides earlier, material‑efficient insight into drug stability and risk.
-
Enhancing Safety In Drug Substance Synthesis: A Smart Approach To Chemical Design
5/6/2026
Discover how safety‑by‑design principles in chemical synthesis help control exothermic reactions, reduce scale‑up risk, and enable safer, more reliable manufacturing of complex drug substances.
-
Chirality In Drug Development: From Racemic Mixtures To Enantiopure Substances
5/6/2026
Chiral crystallization enables efficient production of enantiopure drug substances, improving pharmacological control and safety while supporting scalable, cost‑effective small molecule development.
-
How To Save Significantly On Early-Phase Clinical Supply
5/6/2026
Discover how integrated clinical supply strategies streamline early trials, reduce logistics complexity, cut costs, and ensure timely delivery of investigational products and samples.
-
EMA Support For SMEs Through Scientific Advice And Early Dialogue
5/6/2026
Discover how early engagement with European regulators helps smaller drug developers reduce uncertainty, clarify requirements, and de‑risk innovative programs through early dialogue.
-
Optimising Solubility: Selecting The Right Technology For Early Drug Development
5/6/2026
Discover how selecting the right solubility‑enhancing technology improves early exposure, supports flexible dosing, and lays a strong foundation for downstream oral drug development.
-
Defining Acceptable Impurity Levels For Drug Substances In GLP Toxicology Studies
5/6/2026
Uncover how aligning impurity profiles between toxicology and clinical drug substance builds translational confidence, supports regulatory readiness, and reduces late‑stage development risk.
-
(Cross-) Contamination Control Through Effective Equipment Cleaning
5/6/2026
Discover science-driven cleaning strategies that reduce cross-contamination, enable safe multiproduct manufacturing, and support faster, flexible GMP changeovers.
-
The Importance Of Polymorph Screenings
5/6/2026
Discover how systematic polymorph screening reduces development risk, safeguards product performance, and enables confident solid‑form selection across the drug development lifecycle.
-
Deciphering Nanoparticle Properties With AF4
5/6/2026
Discover how risk‑based, phase‑appropriate synthesis enables safe, efficient production of highly potent compounds while balancing speed, worker safety, and regulatory readiness in early development.